Resolution of adalimumab-induced psoriasis after vitamin D deficiency treatment

Rheumatol Int. 2012 May;32(5):1313-6. doi: 10.1007/s00296-011-1799-9. Epub 2011 Feb 3.

Abstract

Tumoral necrosis factor alpha blockers are very efficient in the treatment of many inflammatory systemic diseases, including rheumatoid arthritis and psoriasis. However, a paradoxical arouse of psoriasiform lesions may occur in a few patients taking anti-TNFα. The etiology of this rare side effect is still a mystery, and its treatment may be difficult. The authors report the resolution of adalimumab-induced psoriasis in a woman with rheumatoid arthritis after the use of high vitamin D(3) doses for the treatment of vitamin D deficiency. This is the first report of resolution of anti-TNFα-induced psoriasiform lesions by high doses of vitamin D(3) in a patient with rheumatoid arthritis and vitamin D deficiency. This case raises interesting questions on the role of vitamin D deficiency in the pathogenesis of this side effect and on the possible usefulness of high-dose vitamin D(3) in its treatment.

Publication types

  • Case Reports

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antirheumatic Agents / adverse effects*
  • Arthritis, Rheumatoid / complications
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / immunology
  • Biomarkers / blood
  • Cholecalciferol / therapeutic use*
  • Drug Substitution
  • Female
  • Humans
  • Middle Aged
  • Psoriasis / chemically induced
  • Psoriasis / drug therapy*
  • Psoriasis / pathology
  • Risk Factors
  • Rituximab
  • Time Factors
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Vitamin D / analogs & derivatives
  • Vitamin D / blood
  • Vitamin D Deficiency / blood
  • Vitamin D Deficiency / complications
  • Vitamin D Deficiency / diagnosis
  • Vitamin D Deficiency / drug therapy*
  • Vitamins / therapeutic use*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents
  • Biomarkers
  • Tumor Necrosis Factor-alpha
  • Vitamins
  • Vitamin D
  • Cholecalciferol
  • Rituximab
  • 25-hydroxyvitamin D
  • Adalimumab